[go: up one dir, main page]

PL1687066T3 - Sposoby modulowania odporności - Google Patents

Sposoby modulowania odporności

Info

Publication number
PL1687066T3
PL1687066T3 PL04810895T PL04810895T PL1687066T3 PL 1687066 T3 PL1687066 T3 PL 1687066T3 PL 04810895 T PL04810895 T PL 04810895T PL 04810895 T PL04810895 T PL 04810895T PL 1687066 T3 PL1687066 T3 PL 1687066T3
Authority
PL
Poland
Prior art keywords
methods
modulating immunity
immunity
modulating
Prior art date
Application number
PL04810895T
Other languages
English (en)
Inventor
Howard Weiner
Mohamed H Sayegh
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34623123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1687066(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of PL1687066T3 publication Critical patent/PL1687066T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04810895T 2003-11-14 2004-11-12 Sposoby modulowania odporności PL1687066T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52014803P 2003-11-14 2003-11-14
US56774104P 2004-05-03 2004-05-03
EP04810895A EP1687066B1 (en) 2003-11-14 2004-11-12 Methods of modulating immunity
PCT/US2004/037910 WO2005048935A2 (en) 2003-11-14 2004-11-12 Methods of modulating immunity

Publications (1)

Publication Number Publication Date
PL1687066T3 true PL1687066T3 (pl) 2013-01-31

Family

ID=34623123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04810895T PL1687066T3 (pl) 2003-11-14 2004-11-12 Sposoby modulowania odporności

Country Status (9)

Country Link
US (3) US7883703B2 (pl)
EP (2) EP2397189B1 (pl)
JP (1) JP5027512B2 (pl)
AU (1) AU2004291107B2 (pl)
CA (1) CA2545806C (pl)
DK (1) DK1687066T3 (pl)
ES (1) ES2393674T3 (pl)
PL (1) PL1687066T3 (pl)
WO (1) WO2005048935A2 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU2004291107B2 (en) 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
CA2614640A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP2023955A4 (en) * 2006-06-06 2009-10-28 Tolerrx Inc Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
SG10201504662WA (en) * 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
JP2010508281A (ja) * 2006-10-26 2010-03-18 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション リン酸塩吸収の低減方法
US20080233132A1 (en) * 2006-11-03 2008-09-25 Miller Stephen D Multiple sclerosis therapy
AU2007337082A1 (en) * 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
US20090131329A1 (en) * 2007-09-14 2009-05-21 Edmund John Miller Treatment for allograft rejection
US20110200617A1 (en) * 2008-01-18 2011-08-18 Yaron Ilan Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
WO2009113065A1 (en) * 2008-03-13 2009-09-17 Hadasit Medical Research Services & Development Ltd. Immuno-modulating compositions for the treatment of immune-mediated disorders
JP5894538B2 (ja) * 2010-02-04 2016-03-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ
EP2563815A2 (en) * 2010-04-29 2013-03-06 Nasvax Ltd. Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
ES2732213T3 (es) 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
US9452219B2 (en) 2011-06-02 2016-09-27 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
ES2893855T3 (es) * 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US20150132289A1 (en) * 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
WO2013186613A1 (en) 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
SG11202011633SA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Psma binding agents and uses thereof
DE102018213030A1 (de) 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
MX2021012767A (es) 2019-04-19 2021-11-18 Janssen Biotech Inc Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US20230227555A1 (en) * 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
CA3210246A1 (en) 2021-01-28 2022-08-04 Janssen Biotech, Inc. Psma binding proteins and uses thereof
US20220332822A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
CA1339070C (en) 1989-01-26 1997-07-29 Wulf Droge Treatment of diseases associated with cysteine deficiency
ATE168272T1 (de) * 1989-10-27 1998-08-15 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
KR0137806B1 (ko) 1991-07-25 1998-04-30 케네쓰 제이. 울코트 사람의 질병 치료를 위한 재조합 항체
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1995000110A1 (en) * 1993-06-28 1995-01-05 Lion Corporation Composition for oral cavity
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2001501622A (ja) * 1996-10-02 2001-02-06 オビミュン インコーポレイテッド 病気を治療するための鶏卵黄抗体の経口投与
AU7467898A (en) * 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
WO2000062806A1 (en) 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
AU6604701A (en) 2000-06-07 2001-12-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the TH1 immune response
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
WO2003041777A1 (en) * 2001-11-14 2003-05-22 Nektar Therapeutics Aerosolization device with improved endpiece connection
EP1472341A4 (en) 2002-02-08 2005-06-15 Xcyte Therapies Inc COMPOSITIONS AND METHODS FOR RESTORING IMMUNE RESPONSE IN PATIENTS WITH IMMUNOLOGICAL DEFICIENCIES
EP1572908A4 (en) 2002-02-14 2008-10-22 William J Rutter CHIMERIC MOLECULES FOR ADMINISTERING CLEAVAGE TO A TREATED HOST
JP2005526769A (ja) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与
WO2004052397A1 (en) * 2002-12-05 2004-06-24 Protein Design Labs, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
EP1660534A2 (en) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
AU2004291107B2 (en) * 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
IL172175A0 (en) * 2005-11-24 2011-08-01 Hadasit Med Res Service Beta glycolipids as immuno-modulators
US20110200617A1 (en) 2008-01-18 2011-08-18 Yaron Ilan Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Also Published As

Publication number Publication date
JP5027512B2 (ja) 2012-09-19
JP2007511529A (ja) 2007-05-10
US20050196395A1 (en) 2005-09-08
EP1687066A4 (en) 2008-09-24
EP1687066B1 (en) 2012-08-29
AU2004291107A1 (en) 2005-06-02
CA2545806A1 (en) 2005-06-02
HK1098085A1 (en) 2007-07-13
WO2005048935A3 (en) 2006-03-30
CA2545806C (en) 2014-09-16
EP2397189A1 (en) 2011-12-21
US20150064197A1 (en) 2015-03-05
US7883703B2 (en) 2011-02-08
AU2004291107B2 (en) 2010-09-30
ES2393674T3 (es) 2012-12-27
EP1687066A2 (en) 2006-08-09
DK1687066T3 (da) 2012-11-26
US9850305B2 (en) 2017-12-26
EP2397189B1 (en) 2015-03-18
US20110165177A1 (en) 2011-07-07
WO2005048935A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
PL1687066T3 (pl) Sposoby modulowania odporności
GB0325192D0 (en) Method of use
GB0326439D0 (en) Methods
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
GB0325442D0 (en) Plug
AU157323S (en) Set of bottles
GB2407131B (en) Modulator
GB0306575D0 (en) Modulators
GB0328243D0 (en) Methods
EP1592431A4 (en) METHOD FOR MODULATING IL-6
GB2407928B (en) Signalling method
AU2003295790A8 (en) Modulation of iap-like expression
GB0219723D0 (en) Methods
GB2401551B (en) Stimulation aid
GB0327909D0 (en) Methods
GB0327368D0 (en) Methods
GB0320627D0 (en) Methods
GB0327955D0 (en) Teaching aid
IL158599A0 (en) Methods of modulating hematopoiesis
GB0315827D0 (en) Methods
GB0307076D0 (en) Methods
GB2408837B (en) Teaching aid
GB0305252D0 (en) Methods
GB0323793D0 (en) Methods
GB0303183D0 (en) Operation of trains